Publications by authors named "Mai Takata"
Objectives: The aim of this article is to investigate the efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis.
Methods: Post hoc subgroup analysis of a global, randomised, controlled trial in patients treated with weekly tocilizumab 162 mg or placebo subcutaneously in a 48-week double-blind period (tocilizumab and placebo groups) followed by tocilizumab for 48 weeks in an open-label extension (continuous-tocilizumab and placebo-tocilizumab groups).
Results: Among 20 patients, 12 were randomised to tocilizumab (all had interstitial lung disease) and eight were randomised to placebo (six had interstitial lung disease).
Article Synopsis
- * A new measure, ΔPID, representing the difference in AMU from 2013 to 2016, was created and compared with existing data from Japan and its prefectures.
- * Findings indicated significant inconsistencies in AMU changes at the secondary medical area level, highlighting the need for more localized assessments to effectively address antimicrobial resistance.